NIAID's Triple Threat: Closed Doors on Trial Funding
Published Date: 3/19/2025
Notice
Summary
The National Institute of Allergy and Infectious Diseases is holding a closed meeting on April 7, 2025, to review important grant applications for clinical trial projects. This meeting affects researchers seeking funding and keeps sensitive info private. It’s a key step in deciding who gets money to fight infectious diseases.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Researchers' Grant Applications Reviewed
If you are a researcher applying for the NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required), your grant application will be reviewed on April 7, 2025 from 12:00 p.m. to 3:30 p.m. at NIAID (video-assisted). This meeting is a formal step in deciding who receives federal funding to support clinical trial projects against infectious diseases.
Confidentiality Protections for Applicants
The meeting will be closed to the public under 5 U.S.C. 552b(c)(4) and 552b(c)(6) to protect confidential trade secrets, commercial property (including patentable material), and personal information about grant applicants. This keeps sensitive research details and applicant personal data private during the grant review on April 7, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-17899, Proposed Collection; 60-Day Comment Request; Assurance (Interinstitutional, Foreign, and Domestic) and Annual Report (Office of the Director)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the Office of Laboratory Animal Welfare (OLAW) in the Office of Extramural Research (OER) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-17687, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in October 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, ensuring fair and confidential decisions. Scientists applying for grants in genetics, molecular sciences, oral health, and cancer research are the ones affected, with no direct cost changes announced.
2026-17438, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings in late September 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers applying for funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
Previous / Next Documents
Previous: 2025-04565, National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
The National Institute of Allergy and Infectious Diseases is holding a closed meeting on April 18, 2025, to review important grant applications related to clinical trials and research projects. This meeting affects researchers seeking funding and keeps sensitive information private. It’s a key step in deciding who gets money to fight infectious diseases and allergies.
Next: 2025-04568, Administrative Disaster Declaration of a Rural Area for the State of Alaska
Alaska just got hit hard by a severe storm and flooding, so the government declared a disaster for a rural area on March 13, 2025. This means folks living there can get extra help and money to recover faster. If you’re in the affected area, expect quicker aid and support to rebuild your homes and community.